Staff >> Faculty >> Dr. Vikram Mathews

Dr. Vikram Mathews MBBS, MD, DM

Professor & Head, Department of Haematology

Career Interests

Major areas of clinical and laboratory research are

• Acute myeloid leukemia
• Acute Promyelocytic leukemia
• Evaluation of mechanisms of resistance to arsenic trioxide and impact of novel agents in the management of acute promyelocytic leukemia
• Allogeneic stem cell transplant. Improving clinical outcomes by studying risk stratification, modifying conditioning regimens and graft manipulation.
• Study of inhibitors in hemophilia.

Awards

• Early career investigator award from Bayer Hemophilia Awards program 2006
• Best abstract and oral presentation award. Asia Pacific BMT meeting. Phuket, Thailand 2010

Reviewer for the following journals

• Indian Journal of Haematology and Transfusion (also editorial board)
• Indian Journal of Medical Research
• Indian Journal of Pathology and Microbiology
• Pediatric Blood and Cancer
• Blood
• Biology of Blood and Marrow Transplantation
   

Research Projects

Research grants / Fellowships from other funding agencies

PI	Nature of Funding (Grant/ Fellowship)	Awarding Agency	Title of the project	Amount awarded (lakhs)	Start date (mm/yy)	End date (mm/yy)
1	Grant	CEFIPRA	Evaluation of cellular and immune response in mice and men following treatment with ATO	41.7	05/11	05/14
	Grant	DBT	Evaluation of molecular markers in AML	49.52	04/09	04/14
	Grant	BMS	Dasatinib vs. standard dose imatinib phase III study	17	05/08	04/13
	Grant	DBT	Evaluation of resistance to arsenic trioxide in APL	58.77	04/07	04/10
	Grant	Bayer Hemophilia  Awards Program	Prevalence of inhibitors in patients with severe hemophilia A	76.12	04/06	04/08

Bio Data

Date from (mm/yy)	Date to (mm/yy)	Degree	Subject	University/Institution
06/85	03/91	MBBS	Medicine	Dr.MGR University
03/93	03/96	MD	General Medicine	Dr.MGR University
03/99	03/01	DM	Clinical Haematology	Dr.MGR University
03/01	03/03	Post doctoral fellow	Stem cell biology	Washington University, St. Louis. USA
04/03	04/04	BoneMarrow Transplant fellowship	BMT and Leukemia	Washington University, St. Louis. USA

Email: vikram@cmcvellore.ac.in
Phone: +91 416-2282891

Selected Publications

• Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Br J Haematol. 2001;113:257-258.
• Mathews V, Chandy M, Srivastava A. Arsenic trioxide in the management of acute promyelocytic leukaemia. Natl Med J India. 2001;14:215-222.
• Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol. 2002;70:292-299.
• George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18:1587-1590.
• Mathews V, Desire S, George B, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006.
• Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632.
• Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994-995.
• Thirugnanam R, George B, Chendamarai E, Viswabandya A, Chandy M, Srivastava A, Mathews V. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009;15:1479-1484.
• Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866-3871.

http://www.ncbi.nlm.nih.gov/pubmed?term=Vikram Mathews